Reformulation has Ruled in Neurology Dealmaking--Until Now
The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.
You may also be interested in...
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
Pfizer's proposed acquisition of Rinat Neuroscience is the costliest private biotech purchase yet--it paid $500 million in cash for the CNS play. What's more extraordinary still is that the most valuable asset at Rinat is pre-clinical.
Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.